Testosterone prescriptions for women rose sharply despite lack of FDA approval
An analysis by Truveta for Reuters published on September 15 found a surge in female testosterone prescriptions amid pharmacy access issues.
Prescription numbers climb rapidly
Data shows that orders for the hormone increased by 146 percent between January 2023 and July 2026. This growth occurred even though no products currently hold specific FDA approval for female use.
Regulatory status remains unclear
Medical guidelines endorse the treatment for hypoactive sexual desire disorder in postmenopausal patients only. The Food and Drug Administration requested additional data on September 17 to evaluate future product approvals.
Pharmacy access creates hurdles
Patients face delays and denials when seeking these medications at local pharmacies. Researchers note that more study is required to confirm benefits for fatigue or mood changes.
Reported by one outlet
Only one outlet has published this. Nothing here has been checked against a second report, so read it as that outlet's account and follow the link below for the original.
Reported by
1 independent outlet. Headline as published. Links open the original report.